Lundbeck Rises 4% as Nordea Says Buy Undervalued Stock

• (PLX AI) - Lundbeck shares rose 4% in morning trading after Nordea reiterated a buy recommendation on the stock, saying it was undervalued.
• • Price target raised to DKK 271 from DKK 265
• • Lundbeck has prospects for significant sales acceleration on Vyepti for migraines, Nordea said
• • Vyepti is positioned to win in the long term, and the stock is at substantial discount valuation to the sector, analysts at Bank of America said
• • However, near-term growth is heavily predicated on Vyepti, accounting for 65% of Lundbeck's consensus growth, and with questions whether this can be achieved, BofA said, reiterating a neutral recommendation, but lifting the price target to DKK 185 from DKK 170